NEW YORK, Jan. 6, 2016 /PRNewswire/ -- RDD Pharma, a specialty pharma company focused on innovative therapies for anorectal diseases and gastrointestinal disorders, today announced the appointment of Michael Rice to its Board of Directors. Mr. Rice brings experience in finance and capital markets focused on life sciences.
"It is our pleasure to welcome Michael to our Board of Directors during an exciting stage of our company's growth," said Jason Laufer, CEO of RDD Pharma. "Michael's insight and guidance will be invaluable as we move our products into later stage clinical development and identify the best commercialization paths."
"I am pleased to be joining RDD Pharma's Board at such a critical juncture in the Company's history," said Mr. Rice. "With a phase 3 clinical trial set to begin shortly for RDD's lead product candidate, RDD-1219, for the treatment of pain associated with anal fissure, and a phase 2b study expected to initiate later in 2016 for RDD-0315, being developed as a potential treatment for fecal incontinence, the Company is fast-approaching multiple key value inflection points. I look forward to supporting RDD in its future strategic endeavors."
Michael Rice, founder of LifeSci Advisors, is a Founding Partner of LifeSci Advisors, a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach, and LifeSci Capital, a research-driven investment bank with deep domain expertise in the life sciences. Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael is a former Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets – including the structuring and execution of numerous transactions. Michael also served as a Managing Director at Bank of America specializing in large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
About RDD Pharma
RDD is a privately held specialty pharma company, backed by Orbimed. RDD focuses on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders. RDD Pharma's lead product for the treatment of pain associated with anal fissure is starting Phase 3 in Europe in Q1, 2016. RDD-0315 for fecal incontinence is the midst of Phase 2b preparations. Products currently under development at RDD are expected to reach the market in two to six years.
Jennifer Filbey, Ph.D.
Business & Corporate Development
SOURCE RDD Pharma